Sign in
Taking people in South KoreaNo phase

Follows Korean adults taking atogepant to prevent migraine

Studies safety and effect of atogepant in Korean adults with migraine in routine care.

Key facts

Who runs it
AbbVie
Where
Ansan-si, Busan, Changwon-si, Daegu, Daejeon, Gangwon-do, Goyang, Goyang-si, Gwangju, Hwaseong, Hwaseong-si, Iksan, Incheon, Jeonju, Seongnam-si, Seoul, Suwon, Uijeongbu-si, and Yongin-si, South KoreaSee the 36 sites
Trial code
Registry title
Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine
Status
Recruiting
People taking part
3,000 people, planned
Started
24 Sept 2024
Expected to end
May 2029
Type of study
Observational
Treatments tested
  • Atogepant
Record updated
22 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for Korean adults with migraine who have been prescribed atogepant by their doctor under the approved local label.

Age
19 years and older
Sex
All
Disease stage
Migraine, either chronic or episodic

Main reasons for not taking part

  • Any contraindication to atogepant listed on the approved local label
  • Currently taking part in another clinical research study, except an observational study

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Participants with migraine suitable for the treatment with atogepant according to the latest approved local label
  • Participants prescribed atogepant in accordance with the approved local label

Who cannot take part

  • Participants with any contraindication to atogepant as listed on the latest approved local label
  • Participants currently participating in another clinical research except observational study

Where in South Korea

  • Korea University Ansan HospitalAnsan-si, South KoreaContact: Celine ImTaking people
  • Dong-A University Medical CenterBusan, South KoreaContact: Celine ImTaking people
  • On HospitalBusan, South KoreaContact: Celine ImTaking people
  • Ryu Sang Hyo Neurosurgery ClinicBusan, South KoreaContact: Celine ImTaking people
  • Changwon Fatima HospitalChangwon-si, South KoreaContact: Celine ImTaking people
  • Daegu Catholic University Medical CenterDaegu, South KoreaContact: Celine ImTaking people
  • Keimyung University Dongsan HospitalDaegu, South KoreaContact: Celine ImTaking people
  • Chungnam National University HospitalDaejeon, South KoreaContact: Celine ImTaking people
  • Chuncheon Sacred Heart HospitalGangwon-do, South KoreaContact: Celine ImTaking people
  • Inje University - Ilsan Paik HospitalGoyang, South KoreaContact: Celine ImTaking people
  • National Health Insurance Corporation Ilsan HospitalGoyang-si, South KoreaContact: Celine ImTaking people
  • Chonnam National University HospitalGwangju, South KoreaContact: Celine ImTaking people
  • Hallym University Dongtan Sacred Heart HospitalHwaseong, South KoreaContact: Celine ImTaking people
  • Hallym University Dongtan Sacred Heart HospitalHwaseong, South KoreaContact: Celine ImTaking people
  • Life Neurology ClinicHwaseong-si, South KoreaContact: Celine ImTaking people
  • Teunteun HospitalHwaseong-si, South KoreaContact: Celine ImTaking people
  • Wonkwang University HospitalIksan, South KoreaContact: Celine ImTaking people
  • Gachon University Gil Medical CenterIncheon, South KoreaContact: Celine ImTaking people
  • Inha University HospitalIncheon, South KoreaContact: Celine ImTaking people
  • The Catholic University of Korea, Incheon St. Mary's HospitalIncheon, South KoreaContact: Celine ImTaking people
  • Jeonbuk National University HospitalJeonju, South KoreaContact: Celine ImTaking people
  • Seoul National University Bundang HospitalSeongnam-si, South KoreaContact: Celine ImTaking people
  • Ewha Womans University Medical CentreSeoul, South KoreaContact: Celine ImTaking people
  • Hallym University Kangdong Sacred Heart HospitalSeoul, South KoreaContact: Celine ImTaking people
  • Kangbuk Samsung HospitalSeoul, South KoreaContact: Celine ImTaking people
  • Korea University Anam HospitalSeoul, South KoreaContact: Celine ImTaking people
  • Korea University Guro HospitalSeoul, South KoreaContact: Celine ImTaking people
  • Nowon Eulji Medical Center, Eulji UniversitySeoul, South KoreaContact: Celine ImTaking people
  • Samsung Medical CenterSeoul, South KoreaContact: Celine ImTaking people
  • Seoul National University HospitalSeoul, South KoreaContact: Celine ImTaking people
  • Seoul National University HospitalSeoul, South KoreaContact: Celine ImTaking people
  • Yonsei University Health System Severance HospitalSeoul, South KoreaContact: Celine ImTaking people
  • Ajou University Hospital - Suwon-siSuwon, South KoreaContact: Celine ImTaking people
  • Hwahong HospitalSuwon, South KoreaContact: Celine ImTaking people
  • Uijeongbu Eulji Medical Center - Eulji UniversityUijeongbu-si, South KoreaContact: Celine ImTaking people
  • Yongin Severance HospitalYongin-si, South KoreaContact: Celine ImTaking people

About the trial

What the trial wants to find out

Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound. The study will assess the safety and effectiveness of atogepant for the preventive treatment of migraine in Korean adult patients with chronic migraine or episodic migraine under routine clinical practice.

Read full original descriptionShow less

Atogepant is an approved drug for preventive treatment of migraine in adults. Approximately 3000 adult participants who are prescribed atogepant by their doctors will be enrolled in this study in Korea.

Participants will receive atogepant oral tablets as prescribed by their physician. Participants will be followed for up to week 12.

There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.

The group in the trial

  • Atogepant

    Participants will receive atogepant as prescribed by their physician according to the local label.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Post-marketing Surveillance Study to Evaluate the Safety and Effectiveness of Atogepant for the Prevention of Migraine in Korean Adult Patients
Plain-language title
Follows Korean adults taking atogepant to prevent migraineGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
22 July 2026